Intrigued by Tjalma's observation of an increased risk of bone sarcoma in larger breeds of dogs,'
Fraumeni investigated the relation between stature and malignant bone tumours in children and adolescents.2 He found that children with osteosarcoma or Ewing's sarcoma were significantly taller at diagnosis than the control group, who had nonosseous cancers, and suggested that development of these malignant tumours was related to accelerated skeletal growth. After studying 236 children with newly diagnosed acute lymphoblastic leukaemia Broomhall et al reported that these children were significantly taller than normal children, which implied involvement of growth hormone or somatomedin in the development of acute lymphoblastic leukaemia.3 Hancock et (Table) . There were too few patients with brain tumours referred to our centre during this period for them to be included in the analyses.
In general, standing height was used for children aged over 5 years and recumbent length for those under 5.12 Standing height was measured with the child standing erect with closed heels, buttocks, upper part of the back, and occiput against a two metre measuring scale; the head was positioned so that the external auditory meatus and the lower border of the orbit were on a plane parallel to the floor. Recumbent length was measured with the child lying on a firm table with the soles of feet held firmly against a fixed upright placed at the zero mark; a movable upright was then brought firmly against the vertex.
Heights at diagnosis of these children and adolescents were compared with normal values produced by the National Center for Health Statistics (NCHS). 13 The 5th, 10th, 25th, 50th, 75th, 90th, and 95th centile heights for boys and girls up to 18 years group.bmj.com on June 24, 2017 -Published by http://adc.bmj.com/ Downloaded from identify the number of separate (but not independent) statistical tests that were actually conducted. As there were 10 categories of disease and we wished to examine the results for boys and girls separately we arbitrarily chose k=20 for a significant value-that is, an individual p value must be less than 0-05/20=0-0025 to be declared significant at the 0*05 level-even though additional tests-for example, by age-were also performed.
A more important criticism of the significance testing approach is that it fails to consider the magnitude of the observed deviation from normality. With large numbers of patients, a significant difference may be clinically unimportant and, conversely, with a small number of patients, a large and potentially important difference may be missed. Accordingly, the actual differences (in cm) for a given category are of more importance than a simple 'significant' or 'not significant' result. These data are given for the category with the smallest nominal p value.
Results
No significant difference in average height from the controls was found for any of the patients with the 10 categories of disease based on the adjusted significance level (Table) . Even when the analyses were performed after further dividing patients by age-for example, above or below 1 year for neuroblastoma-no significant difference was achieved. Few of the nominal p values were below 0-05. (Table) . We could also have reported that boys with acute lymphoblastic leukaemia or girls with non-Hodgkin's lymphoma or Hodgkin's disease were taller from this study. Obviously, however, no appreciable difference in height can be observed for girls with Hodgkin's disease in this study (Fig. 1) .
The reliability of the actual height measurements for the study population are rarely discussed. These studies, including the present one, are usually retrospective analyses of height data that were routinely collected, and systematic bias is always a possibility. This is especially important in a small series because the observed average height differences, even if assumed to be real, are very small in absolute magnitude.
Control populations also need careful evaluation because any deviations from the average height of healthy children of the same age, race, and sex are critical in these studies. The use of accurate published norms may seem preferable to any internal control population, but the use of internal controls measured in the same way as patients can obviate any systematic bias in measurement, even though it would be difficult to ascertain selection bias in the controls. There is no simple 'best way' to proceed, but the possibility of inadequate or improper comparisons must be considered in evaluating the publications on this topic.
Another explanation for conflicting reports is variation in the number of patients studied. For example, we were more likely to detect a small deviation from normal heights in patients with acute lymphoblastic leukaemia (n=1591) than in patients with retinoblastoma (n=101). In fact, the observed average height of boys with retinoblastoma deviated most from the average height of any normal subgroup, but it was not significant because of the small number of patients (n=53). Caution is advised with respect to any conclusion drawn from small numbers of patients in these types of studies. A rough rule of thumb is that there should be at least 100 patients in the category under study. This would permit detection with a high probability (0-90) of any deviation from normality over 0-1 standard deviation in average height and would provide reasonable precision in the estimated distribution of heights.
A cautionary note should also be made about the interpretation of results of significance testing. Overreliance on these results impedes a balanced assessment of the magnitude and precision of the observed difference and the medical importance of that difference. The significance tests normally used in these settings, even if proper adjustment for multiplicity is made, can only discriminate between the true difference and zero. Any observed difference will be declared significant if enough patients are included. An estimate of the magnitude of the differences is needed along with an estimate of its precision or standard error. For example, estimates and confidence intervals for the true height differences are more informative than simple significance tests.
Several investigators have suggested that growth hormone may influence the development and proliferation of acute lymphoblastic leukaemia.'5 Increased serum growth hormone and somatomedin concentrations were found at diagnosis of childhood acute lymphoblastic leukaemia in one study.7 None the less any effect of growth hormone during the period of development of leukaemia seems to be clinically unimportant.
We conclude that there is no significant aberrant growth or stature associated with childhood malignancies at presentation. Future studies in this area should consider carefully the potential problems of measurement bias, inadequate comparison populations, small number of patients, subgroup analyses, and overreliance on simple significance testing. A satisfactory growth responise was obtained in 10 of the 23 children, but the children in each group displayed a differing pattern of response. Six of the hypopituitary patients had a disappointing growth response and the one patient in this group who had a good response may not, in fact, hiave been a ciase of congenital hypopituitarism. The authors commcnted that protein anabolic agents were no substitute for the growth hormone. None the less they concluded thalt they should be used in hypopituitiarism despite their poor eff'ect on growth promotion and that it was saf'e to use them when skeletal maturation is retarded (especially in late maturing boys) and in primordial dwart's with a retarded bone age.
Comment. Humran growth hormone first became availlble in restricted amounts cabout the time of publication of this paper and in the ensuing 25 years has completely altered the outlook f'or children suf'f'ering f'rom hypopituitarism. The aidvent of biosynthetic growth hormonc is likely to result in f'urther pronounced changes in the treatmcnt of retarded growth provided adequate aimounts can be marketed at reasonable cost. The place of anabolic steroids in the treaitment of retarded growth is today evcn more problematical than it was in 1962. It is, indeed, very doubtful if they have any place in the treatment of' children suf'fering from growth retardation f'rom whatever cause. 
